This effect was associated with increase of anti-tumor activity of AZD4635 and an anti-PD-L1 mAb in combination, in contrast, efficacy of the dual combination of AZD4635 and CD73 mAb was limited by activation of PD-L1 and ISC pathways (Supplementary Figure S8). This evidence concerns the gene NT5E and neoplasm.